CA2377999A1 - Compositions and methods for raising hdl cholesterol levels - Google Patents

Compositions and methods for raising hdl cholesterol levels Download PDF

Info

Publication number
CA2377999A1
CA2377999A1 CA002377999A CA2377999A CA2377999A1 CA 2377999 A1 CA2377999 A1 CA 2377999A1 CA 002377999 A CA002377999 A CA 002377999A CA 2377999 A CA2377999 A CA 2377999A CA 2377999 A1 CA2377999 A1 CA 2377999A1
Authority
CA
Canada
Prior art keywords
accordance
alkyl
group
lxr agonist
lxr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002377999A
Other languages
English (en)
French (fr)
Inventor
Bei Shan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tularik Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2377999A1 publication Critical patent/CA2377999A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002377999A 1999-07-08 2000-07-07 Compositions and methods for raising hdl cholesterol levels Abandoned CA2377999A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14299499P 1999-07-08 1999-07-08
US60/142,994 1999-07-08
US61213500A 2000-07-07 2000-07-07
US09/612,135 2000-07-07
PCT/US2000/018533 WO2001003705A1 (en) 1999-07-08 2000-07-07 Compositions and methods for raising hdl cholesterol levels

Publications (1)

Publication Number Publication Date
CA2377999A1 true CA2377999A1 (en) 2001-01-18

Family

ID=26840588

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002377999A Abandoned CA2377999A1 (en) 1999-07-08 2000-07-07 Compositions and methods for raising hdl cholesterol levels

Country Status (5)

Country Link
EP (1) EP1212065A4 (de)
JP (1) JP2004500332A (de)
AU (1) AU6074700A (de)
CA (1) CA2377999A1 (de)
WO (1) WO2001003705A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076376B2 (en) 2005-07-22 2011-12-13 Powers Jay P Aniline sulfonamide derivatives and their uses

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO2001015676A2 (en) * 1999-09-01 2001-03-08 University Of British Columbia Compositions and methods for modulating hdl cholesterol and triglyceride levels
US20020048572A1 (en) * 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
JP4267920B2 (ja) 2001-01-26 2009-05-27 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤
US7385063B2 (en) 2001-01-26 2008-06-10 Chugai Seiyaku Kabushiki Kaisha Method for preparing imidazole derivatives
CA2735478C (en) * 2001-01-26 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US7709510B2 (en) 2001-02-20 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators
JP4155351B2 (ja) 2001-02-20 2008-09-24 中外製薬株式会社 代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤としてのアゾール
WO2002077229A2 (en) * 2001-03-01 2002-10-03 Lion Bioscience Ag Cofactors of the liver x receptor alpha and methods of use
JP2004526778A (ja) 2001-04-18 2004-09-02 ジェンザイム コーポレーション 脂肪族ポリアミンを用いるｘ症候群の処置方法
EP1285662A1 (de) * 2001-08-20 2003-02-26 ZLB Bioplasma AG Rekonstituiertes High-Density -Lipoprotein zur Behandlung von Schlaganfällen und Ischämiezuständen
US20040266660A1 (en) 2001-08-20 2004-12-30 Alphonse Hubsch Hdl for the treatment of stroke and other ischemic conditions
US6924311B2 (en) * 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
AU2003223684A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators for the treatment of cardiovascular diseases
AU2003228614A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) * 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
EP1646394A2 (de) * 2003-07-22 2006-04-19 Glaxo Group Limited Behandlungsverfahren mit lxr-agonisten
US7696365B2 (en) 2003-08-01 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Heterocyclic compounds useful as malonyl-CoA decarboxylase inhibitors
EP2208495B1 (de) 2003-08-01 2011-12-14 Chugai Seiyaku Kabushiki Kaisha Azol-Verbindungen auf Cyanoguanidin-Basis als Malonyl-Coa Decarboxylase-Hemmer
ATE400272T1 (de) 2003-08-01 2008-07-15 Chugai Pharmaceutical Co Ltd Piperidin-verbindungen als malonyl-coa decarboxylase-hemmer
DE602004009582T2 (de) 2003-08-01 2009-01-02 Chugai Seiyaku K.K. Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
JP2008526841A (ja) 2005-01-10 2008-07-24 アストラゼネカ アクチボラグ 肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
SE0500056D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 4
SE0500055D0 (sv) * 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
EP1838685A4 (de) * 2005-01-10 2010-01-27 Astrazeneca Ab Derivate von isothiazol-3-(2h)-thion-1,1-dioxiden als liver-x-rezeptormodulatoren
MX2008000141A (es) 2005-06-27 2008-04-07 Exelixis Inc Moduladores de lxr basados en imidazol.
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP2615094A4 (de) 2010-09-07 2013-09-18 Snu R&Db Foundation Sesterterpenverbindungen und ihre verwendung
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
CN105250253B (zh) * 2015-10-30 2018-06-26 黄恺 T0901317作为parp1抑制剂的应用
KR101947976B1 (ko) 2015-12-15 2019-02-13 아스트라제네카 아베 이소인돌 화합물
CN110730780A (zh) 2017-06-14 2020-01-24 阿斯利康(瑞典)有限公司 用作ROR-γ调节剂的2，3-二氢异吲哚-1-甲酰胺

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES442992A1 (es) * 1974-12-02 1977-08-01 Scherico Ltd Un procedimiento para preparar 2-anilino-oxazolinas.
AU2051600A (en) * 1998-12-10 2000-06-26 Board Of Regents, The University Of Texas System Compositions and methods of modulating cholesterol metabolism
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
BR0011696A (pt) * 1999-06-18 2002-04-30 Cv Therapeutics Inc Composições e métodos para aumento do efluxo de colesterol e elevação de hdl usando proteìna abc1 transportadora de cassete de ligação de atp

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076376B2 (en) 2005-07-22 2011-12-13 Powers Jay P Aniline sulfonamide derivatives and their uses

Also Published As

Publication number Publication date
WO2001003705A1 (en) 2001-01-18
EP1212065A4 (de) 2004-02-11
AU6074700A (en) 2001-01-30
EP1212065A1 (de) 2002-06-12
JP2004500332A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CA2377999A1 (en) Compositions and methods for raising hdl cholesterol levels
Wang et al. Drug-drug cocrystals: Opportunities and challenges
Kavanagh et al. Pharmaceutical cocrystals: from serendipity to design to application
Almansa et al. Co-Crystal of Tramadol hydrochloride–Celecoxib (CTC): a novel API–API co-crystal for the treatment of pain
Cao et al. Design, synthesis, and evaluation of in vitro and in vivo anticancer activity of 4-substituted coumarins: a novel class of potent tubulin polymerization inhibitors
Atanasov et al. Honokiol: a non-adipogenic PPARγ agonist from nature
KR101679400B1 (ko) 트라마돌 및 ＮＳＡＩＤｓ의 공결정
ES2853485T3 (es) Derivado de urea como compuesto inhibidor de Trk
ES2544482T3 (es) Compuesto rexinoide que tiene un grupo alcoxi
US5798374A (en) Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
Urban et al. Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction
WO2007111994A2 (en) Compounds and methods for treatment of disorders associated with er stress
PT1302461E (pt) Inibidores de produção de tnf-alpha
Mantlo et al. Update on the discovery and development of cholesteryl ester transfer protein inhibitors for reducing residual cardiovascular risk
JP2016522831A (ja) 炎症を予防および治療するためのクリオピリン阻害剤
AU753657B2 (en) Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
Amrutha et al. Enhanced Aqueous Solubility of the Solid Forms of a BCS Class-II Anti-Tuberculosis Drug, Prothionamide
Anand et al. Prediction of activity spectra of substances assisted prediction of biological activity spectra of potential anti-Alzheimer’s phytoconstituents
Gao et al. Design, synthesis and pharmacological evaluation of naphthofuran derivatives as potent SIRT1 activators
Al-Wahaibi et al. Probing the effect of halogen substituents (Br, Cl, and F) on the non-covalent interactions in 1-(adamantan-1-yl)-3-arylthiourea derivatives: A theoretical study
JP2016519662A (ja) Ｋ２ｐチャネルの調節
Deng et al. Identification of novel dual-target estrogen receptor α degraders with tubulin inhibitory activity for the treatment of endocrine-resistant breast cancer
Dawson et al. Adamantyl-substituted retinoid-derived molecules that interact with the orphan nuclear receptor small heterodimer partner: effects of replacing the 1-adamantyl or hydroxyl group on inhibition of cancer cell growth, induction of cancer cell apoptosis, and inhibition of SRC homology 2 domain-containing protein tyrosine phosphatase-2 activity
Gabriele et al. Methanethiosulfonate derivatives as ligands of the STAT3-SH2 domain
Zuo et al. Design and synthesis of an N-benzyl 5-(4-sulfamoylbenzylidene-2-thioxothiazolidin-4-one scaffold as a novel NLRP3 inflammasome inhibitor

Legal Events

Date Code Title Description
FZDE Dead